The University of Nevada, Reno School of Medicine

Setting Sights Higher With New and Emerging TYK2 Inhibitors for Psoriasis

MD, MPH

MD, PhD

Outline the role of new and emerging tyrosine kinase 2 (TYK2) inhibitors in optimizing psoriasis management 


Review the latest clinical data for new and emerging TYK2 inhibitors in the treatment of psoriasis 


Discuss strategies to incorporate more stringent efficacy targets to optimize treatment plans for psoriasis

large_image.png

medium_image.png

small_image.png

thumbnail_image.png

image.png

Psoriasis is a chronic, immune-mediated inflammatory disease characterized by dysregulated IL-23/IL-17 axis signaling and keratinocyte hyperproliferation, resulting in well-demarcated erythematous plaques with silvery scale. Beyond cutaneous involvement, psoriasis has been linked to systemic inflammation contributing to increased risk of cardiometabolic and other inflammatory comorbidities.

This hub gathers the evidence, expert perspective, and practical insight shaping how psoriasis is understood and treated today, connecting advances in targeted therapy with the everyday decisions required to manage chronic inflammation and systemic risk.

FC25: Setting Sights Higher With New and Emerging TYK2 Inhibitors for Psoriasis

About

Learning Objectives

Intended Audience

Faculty

Accreditation Statement

Credit Designation Statement

Disclosures